Covidien reveals that it is under federal subpoena

In its annual 10-K filing with the SEC, Covidien ($COV) quietly noted that it is under a federal subpoena related to some of its peripheral vascular products. "On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General, issued a subpoena requesting production of documents relating to certain of our peripheral vascular products. We are complying as required with the terms of the subpoena," the filing states. Filing

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.